| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/06/2004 | WO2004037976A2 NONSENSE-MEDIATED mRNA DECAY |
| 05/06/2004 | WO2004037972A2 Endogenous retrovirus up-regulated in prostate cancer |
| 05/06/2004 | WO2004037857A1 Bfk protein as therapeutic molecules |
| 05/06/2004 | WO2004037856A2 Plasmodium falciparum virulence factor var o |
| 05/06/2004 | WO2004037295A1 Method and agent for treating vulnerable plaque |
| 05/06/2004 | WO2004037294A2 New settings for recombinant adenoviral-based vaccines |
| 05/06/2004 | WO2004037282A1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 05/06/2004 | WO2004037202A2 Gb virus c and methods of treating viral infections |
| 05/06/2004 | WO2004037188A2 Cardiac muscle regeneration using mesenchymal stem cells |
| 05/06/2004 | WO2004037182A2 Active specific immunotherapy of cancer metastasis |
| 05/06/2004 | WO2004037164A2 Crosslinked compounds and methods of making and using thereof |
| 05/06/2004 | WO2004021992A9 Delivery of therapeutics to the brain and spinal cord |
| 05/06/2004 | WO2004013629A3 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 05/06/2004 | WO2004007662A3 Polymer surfactants for gene therapy applications |
| 05/06/2004 | WO2004001068A3 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 05/06/2004 | WO2003106631A3 Methods and compositions relating to labeled rna molecules that reduce gene expression |
| 05/06/2004 | WO2003099997A3 Methods and compositions for regulation and manipulation of steroidogenesis |
| 05/06/2004 | WO2003099318A3 Pancreas-specific proteins |
| 05/06/2004 | WO2003080804A3 Regulation of ins(3456)p4 signalling by a reversible kinase/phosphatase and methods and compositions related thereto |
| 05/06/2004 | WO2003057843A8 Methods and materials for modulating trpc4 |
| 05/06/2004 | WO2003045316A9 Polynucleotide therapy |
| 05/06/2004 | WO2003022298A3 Use of a protein of the crmp family for treating diseases related to the immune system |
| 05/06/2004 | WO2003010314A3 Gmg-2 polynucleotides and polypeptides and uses thereof |
| 05/06/2004 | WO2002092788A9 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 05/06/2004 | WO2002091995A8 Method to induce neovascular formation and tissue regeneration |
| 05/06/2004 | WO2002088173A3 Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| 05/06/2004 | WO2002087510A3 Subcellular targeting of therapeutic proteins |
| 05/06/2004 | WO2002064737A3 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
| 05/06/2004 | WO2002061113A9 Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| 05/06/2004 | WO2002007757A9 Prevention and treatment of sexual arousal disorders |
| 05/06/2004 | WO2000077167A3 Herpes simplex virus amplicon vector targeting system and method of using same |
| 05/06/2004 | US20040088746 Apoptosis-inducing dna sequences |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087774 Comprises tumor necrosis factor receptor associated factor-(TRAF) inhibitor for diagnosis, prevention and tratment of tumors associated wit h epstein-barr virus |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087537 Compositions comprising fusion polypeptides HIV-Nef and NGF, and methods of using the same |
| 05/06/2004 | US20040087535 Administering a nitric oxide synthase gene in the form of naked dna; angiogenesis inhibitors |
| 05/06/2004 | US20040087532 Vaccine comprising antigen presenting cells loaded with at least two tumor antigens and/or tumor antigen derived peptides |
| 05/06/2004 | US20040087530 SOCS-3 inhibition; increased leptin cell transduction signal-ing; obesity |
| 05/06/2004 | US20040087528 Delivering plasmid vector encoding HERG (A561V) (human ether-a-go-go related gene) protein to cells afflicted with re-entrant atrial flutter mediated cardiac arrhythmia |
| 05/06/2004 | US20040087524 Agent for postoperative use after removal of bone tumours |
| 05/06/2004 | US20040087523 Preventing or delaying infection, inflammation or tumor formation |
| 05/06/2004 | US20040087521 Nucleic acid pharmaceuticals-influenza matrix |
| 05/06/2004 | US20040087478 Discovering pain regulating substances; incubating with then measuring binding to cell synthesized peptide or protein |
| 05/06/2004 | US20040087026 Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof |
| 05/06/2004 | US20040087025 Transfering genetic material into proliferating lymphocytes using phorbol ester, calcium ionophores and lymphocyte receptor/CD3 complexes; gene therapy |
| 05/06/2004 | US20040087024 Comprises polyethylenimine coupled to cyclodextrins; for cell transfection; kits |
| 05/06/2004 | US20040087001 Transgenic viral particles to enhance cell fusion and transfer genetic material into polymorphonuclear leukocytes (PMNL); gene therapy |
| 05/06/2004 | US20040086978 Pancreas-derived plasminogen activator inhibitor |
| 05/06/2004 | US20040086977 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 05/06/2004 | US20040086976 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 05/06/2004 | US20040086974 Comprises human tumor suppressor protein for treatment and prevention of cell proliferative disorders; antitumor/anticarcinogenic/antiproliferative agents |
| 05/06/2004 | US20040086967 Comprises polynucleotide coding tumor markers proteins for diagnosis of pancreatic and colon cancers; antiproliferative agents; wound healing or tissue regeneration |
| 05/06/2004 | US20040086952 Monoclonal antibody comrpising affininty for 5-lipoxygenase activating polypeptide (FLAP) for diagnosis, prevention and treatment of inflamation, asthma and glomerulonephritis; gastric cytoprotective agents |
| 05/06/2004 | US20040086931 Polypeptides and nucleic acids encoding same |
| 05/06/2004 | US20040086913 Human genes and gene expression products XVI |
| 05/06/2004 | US20040086903 Comprises nucleotide sequences coding promoter and retinoid carrier protein for identifying modulator for treatment of fertility disorders |
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086875 Novel proteins and nucleic acids encoding same |
| 05/06/2004 | US20040086863 Comprises pleckstrin homology domain-interacting protein (PHI Protein) for identifying modulator and treatment for cancer and insulin response disorders |
| 05/06/2004 | US20040086846 Using bacterial artificial chromosomes to propagate/replicate viral nucleotide sequences; gene therapy and genetic vaccines |
| 05/06/2004 | US20040086845 Nucleotide sequences coding fusion protein comprising translocation domain for targeting and treating tumors; antitumor agents |
| 05/06/2004 | US20040086525 Polynucleotide sequences of C. pneumoniae for use in preventing and treating Chlamydia infection |
| 05/06/2004 | US20040086522 Strategies to prevent autoimmune disease by vaccination with vaccines based upon Epstein-Barr virus |
| 05/06/2004 | US20040086516 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 05/06/2004 | US20040086503 High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086498 Cancer therapy |
| 05/06/2004 | US20040086497 Cell-matrix structure for implantation stably expressing a gene encoding at least one biological modifier to stop or regress excessive tissue proliferation |
| 05/06/2004 | US20040086494 Immune privileged cells for delivery of proteins and peptides |
| 05/06/2004 | US20040086490 Nucleic acid vector comprising a pair of adeno-associated virus 4 (AAV4) inverted terminal repeats and a promoter between the inverted terminal repeats |
| 05/06/2004 | US20040086488 Retroviral vectors |
| 05/06/2004 | US20040086487 Prevention or the treatment of congestive heart failure or myocardial ishchemia by administering a sphingosine kinase, or an analogue, fragment, or derivative thereof |
| 05/06/2004 | US20040086486 Method of enhancing delivery of a therapeutic nucleic acid |
| 05/06/2004 | US20040086485 Viral vector sequences in plasmid form delivered in-vivo to generate vector producing cells |
| 05/06/2004 | US20040086481 Cationic polymer-nucleic acid complexes and methods of making them |
| 05/06/2004 | EP1416048A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-;defective splicing variant |
| 05/06/2004 | EP1416046A1 Use of histamine receptor h3 gene in controlling body weight or food intake |
| 05/06/2004 | EP1415997A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 05/06/2004 | EP1415664A1 Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds |
| 05/06/2004 | EP1415662A1 Homing autologous cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415661A1 Homing of embryonic stem cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415660A1 Homing donor cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414996A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 05/06/2004 | EP1414983A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/06/2004 | EP1414964A2 Vegf isoform |
| 05/06/2004 | EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 05/06/2004 | EP1414949A1 Cell and transgenic animal modelling human antigenic presentation and their uses |
| 05/06/2004 | EP1414948A2 Inhibition of apoptosis process and improvement of cell performance |
| 05/06/2004 | EP1414853A2 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 05/06/2004 | EP1414851A2 Cellular virus receptors and methods of use. |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414500A2 Akt and regulation of ra synovial fibroblast apoptosis |
| 05/06/2004 | EP1414492A1 Method for treating multiple myeloma |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414477A2 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |